GRDX logo

GRIDAI TECHNOLOGIES CORP

GRDXNASDAQ
๐Ÿ† #4359 by market capUS Equity
$3.23โ–ผ $0.11 (โˆ’3.15%)
Market closed ยท at close
๐Ÿ””
Track GRDX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 3.1%
7dโ–ผ 17.3%
14dโ–ผ 33.8%
30dโ–ผ 42.2%
ytdโ–ผ 28.1%
1yโ–ฒ 19.6%
๐ŸฆMarket Cap
$22M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$3.15 โ€“ $3.52
52-Week Range
$1.87 โ€“ $6.93
Volume (shares)
5,270
Avg Volume (shares)
โ€”
Shares Outstanding
6.8M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$36,251
Last Q Revenue
$85,876
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-5.31
Dividend Yield
โ€”
GRDX logo

GRIDAI TECHNOLOGIES CORP

GRDX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About GRIDAI TECHNOLOGIES CORP

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.